Insights

Why Tonix Pharmaceuticals Got Crushed Today

What happened
Tonix Pharmaceuticals (NASDAQ: TNXP) had to swallow a spoonful of awful medicine on Monday. The company’s stock tumbled by nearly 9% following the release of its latest set of quarterly results.
So what
For its first quarter, Tonix — a pre-revenue biotech — posted a net loss of $26.7 million, or $0.05 per share. This was deeper than the nearly $20.7 million shortfall in the same period last year. The difference was due to higher research and development expenses and general and administrative costs. Both grew by roughly $3 million apiece over that one-year stretch.
Image source: Getty Images.

According to data compiled by Yahoo! Finance, the few analysts tracking Tonix’s stock were collectively expecting that $0.05 net loss.
As is standard for biotech companies in relatively early stages of development, Tonix also provided an update on its pipeline programs. In the earnings release, the company quoted CEO Seth Lederman as saying:

“By the end of this year, we expect to have five central nervous system (CNS) programs in the clinic, led by our most advanced program, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, which is in mid-Phase 3 development. Enrollment has begun for TNX-102 SL in a registration-enabling-Phase 3 clinical trial. TNX-102 SL trials in Long COVID and PTSD are also expected to initiate enrollment in the second quarter of 2022.”

Now what
None of this is particularly alarming — in fact, it’s quite encouraging that the promising TNX-102 SL is going through its paces in a late-stage trial. Yet in today’s deep bear market, nothing less than a home run will move the needle on many stocks, and that’s doubly true for pre-revenue biotechs.
Tonix didn’t deserve the drubbing it took on Monday, and investors interested in the sector should take a hard second look at its stock.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Tonix Pharmaceuticals (NASDAQ: TNXP) had to swallow a spoonful of awful medicine on Monday. The company’s stock tumbled by nearly 9% following the release of its latest set of quarterly results.

So what

For its first quarter, Tonix — a pre-revenue biotech — posted a net loss of $26.7 million, or $0.05 per share. This was deeper than the nearly $20.7 million shortfall in the same period last year. The difference was due to higher research and development expenses and general and administrative costs. Both grew by roughly $3 million apiece over that one-year stretch.

Image source: Getty Images.

According to data compiled by Yahoo! Finance, the few analysts tracking Tonix’s stock were collectively expecting that $0.05 net loss.

As is standard for biotech companies in relatively early stages of development, Tonix also provided an update on its pipeline programs. In the earnings release, the company quoted CEO Seth Lederman as saying:

“By the end of this year, we expect to have five central nervous system (CNS) programs in the clinic, led by our most advanced program, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, which is in mid-Phase 3 development. Enrollment has begun for TNX-102 SL in a registration-enabling-Phase 3 clinical trial. TNX-102 SL trials in Long COVID and PTSD are also expected to initiate enrollment in the second quarter of 2022.”

Now what

None of this is particularly alarming — in fact, it’s quite encouraging that the promising TNX-102 SL is going through its paces in a late-stage trial. Yet in today’s deep bear market, nothing less than a home run will move the needle on many stocks, and that’s doubly true for pre-revenue biotechs.

Tonix didn’t deserve the drubbing it took on Monday, and investors interested in the sector should take a hard second look at its stock.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!